ArticleClinical & developmental immunology2012
Combination immunotherapy with 4-1BBL and CTLA-4 blockade for the treatment of prostate cancer.
Article in Clinical & developmental immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy.Cellular and molecular life sciences : CMLS · 2024Review
- Maslinic acid induces autophagy and ferroptosis via transcriptomic and metabolomic reprogramming in prostate cancer cells.Frontiers in pharmacology · 2024Article
- Agonism of 4-1BB for immune therapy: a perspective on possibilities and complications.Frontiers in immunology · 2023Review
- Compartmentalized spatial profiling of the tumor microenvironment in head and neck squamous cell carcinoma identifies immune checkpoint molecules and tumor necrosis factor receptor superfamily members as biomarkers of response to immunotherapy.Frontiers in immunology · 2023Article
- The Cellular and Molecular Immunotherapy in Prostate Cancer.Vaccines · 2022Review
- Role of CD68 in tumor immunity and prognosis prediction in pan-cancer.Scientific reports · 2022Article
- Modulating Oncolytic Adenovirus Immunotherapy by Driving Two Axes of the Immune System by Expressing 4-1BBL and CD40L.Human gene therapy · 2022Article
- Biomaterials for Mimicking and Modelling Tumor Microenvironment.Advances in experimental medicine and biology · 2022Review
- Lysine Acetylation/Deacetylation Modification of Immune-Related Molecules in Cancer Immunotherapy.Frontiers in immunology · 2022Review
- Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?International journal of molecular sciences · 2021Review
- Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4), and CD137 in cervical carcinoma.International journal of clinical and experimental pathology · 2021Article
- Co-stimulatory agonists: An insight into the immunotherapy of cancer.EXCLI journal · 2021Review
- Clinical application of immune checkpoints in targeted immunotherapy of prostate cancer.Cellular and molecular life sciences : CMLS · 2020Review
- Medical Gas Plasma Jet Technology Targets Murine Melanoma in an Immunogenic Fashion.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2020Article
- PD1 signal transduction pathways in T cells.Oncotarget · 2017Review
- Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF.Frontiers in immunology · 2017Article
- 4-1BB agonism: adding the accelerator to cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2016Review
- Cancer immunotherapy: the beginning of the end of cancer?BMC medicine · 2016Review
- 4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.Frontiers in oncology · 2015Review
- Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy.Journal for immunotherapy of cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune regulation has been shown to be involved in the progressive growth of some murine tumours. Interruption of immune regulatory pathways via activation of 4-1BB or cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) blockade appears to be a promising strategy for cancer immunotherapy. In this study, we examined the effectiveness of 4-1BBL-expressing tumor cell vaccine in combination with CTLA-4 blockade on rejection of murine prostate cancer RM-1. We found that the combination of both a vaccine consisting of 4-1BBL-expressing RM-1 cells and CTLA-4 blockade resulted in regression of RM-1 tumors and a significant increase in survival of the tumour cell recipients, compared to that of either treatment alone. The combined vaccination resulted in higher CTL against RM-1 cells and increased secretion of IFN-γ, TNF-α, and IL-2 in the mix-cultured supernatant. These results suggest that combining activation of 4-1BB and blockade of CTLA-4 may offer a new strategy for prostate cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.